This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Alzheimer’s Disease and Related Disorders Annual
edited by Serge Gauthier and Jeffrey L. Cummings,
255 pp., ill., London, UK, Martin Dunitz, 2000, $69.95
Information pertaining to AD and related disorders is expanding at a rate that rivals any area within the realm of clinical neuroscience. Each week seems to usher in a new set of articles examining the molecular neuropathology or clinical care of persons with dementia. Clinicians and researchers specializing in this area complain of difficulties managing the flow of information, and those new to the study of dementia may not even know where to start. This multiauthored annual edited by Serge Gauthier and Jeffrey L. Cummings endeavors to review the most important topics of the past year in this rapidly growing field. In most respects, the editors and authors have met the task.
The book contains 11 chapters, devoted to the genetics of AD, frontotemporal dementia, dementia with Lewy bodies, dementia with parkinsonism, subcortical vascular dementia, minimal cognitive impairment, functional changes brought about by these diseases, and neuropsychiatric manifestations of dementia. There are three chapters focusing on established and possible future treatments, including cholinesterase inhibitors, hormonal therapies, and anti-inflammatories. The contributors are experienced and regarded as experts on the topics covered in their respective chapters.
The sections devoted to specific diagnostic entities generally follow a format that covers demographics, cognitive and behavioral features, diagnostic criteria, neuropathologic changes, and molecular genetics. The chapters on therapeutic interventions cover the scientific rationale behind their use, pertinent clinical trials, and future considerations.
The initial chapter dealing with the genetics of AD examines the postulated roles that amyloid precursor protein (APP), APOE, presenilin 1 and 2, and chromosome 12 play in disease susceptibility. The author capably describes these genetic abnormalities within a framework of molecular neuropathology that makes a complicated subject clinically grounded …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
